FDA declines expanded use of Dynavax's hepatitis B vaccine on insufficient data

The U.S. drug regulator has declined to approve expanded use of Dynavax Technologies' (DVAX.O) hepatitis B vaccine in a section of patients, citing insufficient data over destruction of some trial documents, the company said on Tuesday.